AOD-9604
Modified fragment of human growth hormone (amino acids 177-191) specifically developed for lipolytic (fat-burning) effects without the side effects of full HGH. Approved in Australia as a dietary supplement.
Last updated:: 06/04/2026
Research Status
ANVISA (Brazil)
Not regulated
FDA (USA)
Compounding only
EMA (Europe)
Not regulated
Mechanism of Action
AOD-9604 corresponds to the C-terminal region of growth hormone, which is responsible for its lipolytic effect. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting IGF-1 levels or causing insulin resistance — unlike full HGH.
Study Protocols
Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.
Lipólise / redução de gordura
Subcutânea (SC)Aplicar em jejum, pela manhã
Fragmento modificado do GH (aa 177-191). Ação lipolítica sem efeitos diabetogênicos do GH. Resultados modestos em humanos.
Benefits
Lipolytic effect
Under researchAnimal studies and phase 2 human trials demonstrated fat reduction effects, but clinical results in humans were modest.
No effect on IGF-1
ProvenUnlike HGH, it does not increase IGF-1 or cause insulin resistance, which reduces its risk profile.
Risks and Side Effects
Uncertain efficacy
Low(N/A)The phase 2b trial in obese humans did not reach the primary endpoint of significant weight loss. Its efficacy as an anti-obesity agent is questionable.
Internet vs. Science
What people say online compared to the actual scientific evidence.
Burns fat without dieting
FalseWhat they claim
Promoted as a peptide that eliminates abdominal fat without the need for diet or exercise.
Actual evidence
Clinical studies in humans showed modest results. The phase 2b trial failed to demonstrate clinically significant weight loss. Far inferior to semaglutide/tirzepatide.
| Claim | O que dizem | Evidência real | Verdict |
|---|---|---|---|
| Burns fat without dieting | Promoted as a peptide that eliminates abdominal fat without the need for diet or exercise. | Clinical studies in humans showed modest results. The phase 2b trial failed to demonstrate clinically significant weight loss. Far inferior to semaglutide/tirzepatide. | False |
Important notice
This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.
How to Obtain
This compound can be prepared by licensed compounding pharmacies with a valid prescription. Consult a physician first.